StemRIM Inc. (JP:4599)
:4599
Want to see JP:4599 full AI Analyst Report?
Top Page
StemRIM Inc.
(4599)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥273.00
▲(7.06% Upside)
Action:Reiterated
Date:03/24/26
The score is driven primarily by weak financial performance—revenue disappearance, large losses, and ongoing cash burn—partly cushioned by an extremely low-debt balance sheet. Technical indicators are neutral to slightly weak with price below key moving averages, and valuation is constrained by loss-making status and no dividend support.
Positive Factors
Very low leverage / near-zero debt
Near-zero debt materially reduces financial risk and gives the company durable flexibility to fund R&D, extend clinical programs, or pursue partnerships without immediate refinancing pressure. This structural balance sheet strength supports strategic options over the next 2–6 months.
Negative Factors
Revenue disappearance and volatile income
Revenue collapsing to zero and a swing from modest profit to multi-year losses sharply reduces visibility into core demand and operating scalability. Reliance on irregular or one-off receipts undermines durable top-line predictability and complicates planning for clinical and commercial investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / near-zero debt
Near-zero debt materially reduces financial risk and gives the company durable flexibility to fund R&D, extend clinical programs, or pursue partnerships without immediate refinancing pressure. This structural balance sheet strength supports strategic options over the next 2–6 months.
Read all positive factors
StemRIM Inc. (4599) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥17.74B
Dividend YieldN/A
Average Volume (3M)122.86K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue GrowthN/A
EPS Growth6.10%
CountryJP
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-31.14
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
StemRIM Inc. Business Overview & Revenue Model
Company Description
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently under...
StemRIM Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 2.35B | 22.98M | 1.40B |
| Gross Profit | -49.50M | -44.35M | 2.30B | 0.00 | 0.00 |
| EBITDA | -1.92B | -2.03B | 190.18M | -1.93B | -550.13M |
| Net Income | -1.93B | -2.02B | 168.35M | -1.95B | -582.45M |
Balance Sheet | |||||
| Total Assets | 7.52B | 9.09B | 10.72B | 9.61B | 10.93B |
| Cash, Cash Equivalents and Short-Term Investments | 6.99B | 8.41B | 10.22B | 8.88B | 10.17B |
| Total Debt | 0.00 | 0.00 | 531.00K | 3.67M | 6.73M |
| Total Liabilities | 210.27M | 194.06M | 348.51M | 207.74M | 231.10M |
| Stockholders Equity | 7.31B | 8.89B | 10.37B | 9.40B | 10.70B |
Cash Flow | |||||
| Free Cash Flow | -1.46B | -1.88B | 1.14B | -1.40B | -608.70M |
| Operating Cash Flow | -1.41B | -1.88B | 1.14B | -1.40B | -519.65M |
| Investing Cash Flow | -42.50M | -4.78M | -344.00K | -330.00K | -92.72M |
| Financing Cash Flow | 41.25M | 78.97M | 202.60M | 112.86M | 109.32M |
StemRIM Inc. Technical Analysis
Negative
255.00
Price Trends
299.56
Negative
297.39
Negative
291.54
Negative
Market Momentum
-4.39
Positive
46.18
Neutral
33.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4599, the sentiment is Negative. The current price of 255 is below the 20-day moving average (MA) of 288.50, below the 50-day MA of 299.56, and below the 200-day MA of 291.54, indicating a bearish trend. The MACD of -4.39 indicates Positive momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 33.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4599.
StemRIM Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥5.89B | 84.49 | ― | 1.24% | -7.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.47B | -32.28 | ― | ― | -11.11% | -187.80% | |
45 Neutral | ¥17.74B | -9.59 | ― | ― | ― | 6.10% | |
43 Neutral | ¥33.35B | -10.48 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥11.98B | -20.34 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.42B | -8.15 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4599
StemRIM Inc.
286.00
-55.00
-16.13%
JP:4593
Healios KK
261.00
-256.00
-49.52%
JP:4880
CellSource Co., Ltd.
301.00
-413.82
-57.89%
JP:4978
ReproCELL Inc.
127.00
-60.00
-32.09%
JP:7774
Japan Tissue Engineering Co., Ltd.
584.00
-20.00
-3.31%
JP:7776
CellSeed Inc.
213.00
-307.00
-59.04%
StemRIM Inc. Corporate Events
StemRIM Plans Tax-Efficient Capital Reduction Ahead of July Extraordinary Meeting
May 13, 2026
StemRIM Inc. has set June 1, 2026 as the record date for shareholders eligible to vote at an extraordinary general meeting scheduled for July 29, 2026 in Osaka. The sole agenda item will be a proposed reduction of the company’s stated capita...
StemRIM Highlights Shionogi’s Timelines for Regenerative Drug Redasemtide in DEB and Stroke
May 12, 2026
StemRIM said partner Shionogi has set out an updated clinical and commercialization timeline for Redasemtide, a peptide drug derived from HMGB1 and licensed from StemRIM as a flagship “Regeneration-Inducing Medicine”. Shionogi is runni...
StemRIM Completes Enrollment in Early-Stage Redasemtide Trial for Ischemic Cardiomyopathy
Apr 15, 2026
StemRIM Inc. said it has completed patient enrollment in a Phase 1/2 investigator-initiated clinical trial of its regeneration-inducing drug candidate redasemtide in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting....
StemRIM Unveils Midterm FY2026 Results and R&D Progress in Regenerative Medicine
Mar 13, 2026
StemRIM Inc. released presentation materials outlining its financial results for the six months ended January 31, 2026 and provided an overview of management indicators, financial summaries, and key business highlights. The update also detailed pr...
StemRIM narrows interim loss as it ramps R&D on regenerative drug pipeline
Mar 11, 2026
StemRIM reported no operating revenue and a net loss of ¥928 million for the six months to Jan. 31, 2026, narrowing slightly from the previous year’s ¥1,048 million loss as basic loss per share improved to ¥14.91. Total assets...
StemRIM Wins Key Patent on Gene Therapy SR-GT1 for Dystrophic Epidermolysis Bullosa
Mar 2, 2026
StemRIM Inc. announced that a Japanese patent has been granted for a stem cell gene therapy technology, SR-GT1, designed to provide a curative treatment for dystrophic epidermolysis bullosa, a severe hereditary skin disorder caused by defects in t...
StemRIM Wins Canadian Patent for Redasemtide Use in Cartilage Disorders
Feb 17, 2026
StemRIM Inc. has secured a forthcoming Canadian patent covering the use of its peptide drug candidate Redasemtide, an HMGB1 fragment peptide, as a therapeutic agent for a broad spectrum of cartilage disorders including osteoarthritis, meniscal dam...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.